ClinicalTrials.gg
CompletedNCT04904913Updated Nov 17, 2025

A Study of IBI362 Evaluating Weight Loss in Obese and Overweight Chinese Subjects

A Phase 2 interventional study of IBI362 and placebo in Overweight/ Obesity, sponsored by Innovent Biologics (Suzhou) Co. Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-11-17.

Sponsored by Innovent Biologics (Suzhou) Co. Ltd. (part of Innovent Biologics, Inc.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
328
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing mazdutide in Obesity — 11 open to participants now, 14 under way, 4 of them phase 3. mazdutide · Obesity.

Enrollment
8th of 22
328 · median 187
Started
2021
with 1 other
Phase 2
5 of 22
2 open now
Registered
3rd of 22
by date
Lead sponsor
12 of 22
Innovent Biologics (Suzhou) Co. Ltd.

Among the 22 studies testing mazdutide in Obesity, this one is the 8th largest by enrollment, is one of 2 that started in 2021, is one of 5 in phase 2, and was the 3rd registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

11 of the 22 studies testing mazdutide in Obesity are open now, in 3 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Where they have run

About mazdutide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing mazdutide in Obesity, or all of them as a file.
02

Study summary

This is a multicenter, double-blind, randomized, placebo-controlled study conducted in overweight or obese subjects. This study is divided into the first stage and the second stage. The participant enrollment and data analysis in the two stage are independent and do not influence each other.

In the first stage of this study, about 240 subjects will be enrolled. Qualified subjects will receive placebo in a 2-week introduction period, after that, they will be randomized to IBI362 low dose, IBI362 moderate dose, IBI362 high dose groups, in every group, subjects will be randomized to IBI362 and placebo groups at a ratio of 3:1. Random stratification is performed based on BMI \< 28.0 kg/㎡ and BMI≥28.0 kg/㎡. The subjects received drug administration once weekly. The entire trial covers a 3-week screening period, a 2-week placebo introduction period, a-24 week double-blind treatment period, and a 12-week drug discontinuation follow-up period. During the entire research period, the subjects shall maintain diet and exercise control.

The second stage is IBI362 extra high dose study, about 80 subjects will be enrolled. Qualified participants will receive placebo in a 2-week introduction period, after that, they will be randomized to IBI362 extra high dose and placebo groups at a ratio of 3:1. The subjects received drug administration once weekly. The entire trial covers a 3-week screening period, a 2-week placebo introduction period, a 24-week double-blind treatment period, a 24-week extended treatment period, and a 12-week drug discontinuation follow-up period. The 24-week extended treatment period is optional. During the entire research period, the subjects shall maintain diet and exercise control.

03

Conditions studied

  • Overweight/ Obesity
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The first stage: (BMI) ≥28 kilograms per square meter (kg/m²), or ≥24 kg/m² with at least one of the following comorbidities: hyperphagia, pre-diabetes, hypertension, dyslipidemia, fatty liver disease, weight-bearing joint pain, obesity-induced dyspnea or obstructive sleep apnea syndrome; The second stage: Body mass Index (BMI) ≥30 kilograms per square meter (kg/m²)
  2. The weight change of the subjects before and after the introduction period was less than 5.0%

Exclusion criteria

Exclusion Criteria:

  1. Diabetes mellitus
  2. Weight change > 5.0% after diet and exercise control for at least 12 weeks before screening
  3. Have used or are currently using weight loss drugs within 3 months before screening
  4. History of pancreatitis
  5. Family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2)
  6. History of moderate to severe depression,or have a history of serious mental illness
  7. Any lifetime history of a suicide attempt
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
328 participants (actual)

Study arms

  • Experimental
    IBI362 high dose

    high dose IBI362 administered subcutaneously (SC) once a week.

    Drug: IBI362

  • Experimental
    IBI362 low dose

    Low dose IBI362 administered subcutaneously (SC) once a week.

    Drug: IBI362

  • Placebo comparator
    placebo

    placebo administered subcutaneously (SC) once a week.

    Other: placebo

  • Experimental
    IBI362 moderate dose

    moderate dose IBI362 administered subcutaneously (SC) once a week.

    Drug: IBI362

  • Experimental
    IBI362 extra high dose

    extra high dose IBI362 administered subcutaneously (SC) once a week.

    Drug: IBI362

Interventions

  • DrugIBI362

    IBI362 administered subcutaneously (SC) once a week.

  • Otherplacebo

    placebo administered subcutaneously (SC) once a week.

06

What researchers measure

Primary outcomes

  1. Percent Change from Baseline in Body Weight

    Percent Change from Baseline in Body Weight

    Time frame: Baseline ,week 24

Secondary outcomes

  1. Percentage of Participants who Achieve ≥5% Body Weight Reduction

    Time frame: Baseline, Week 24

  2. Percentage of Participants who Achieve ≥10% Body Weight Reduction

    Time frame: Baseline, Week 24

  3. Absolute change from Baseline in body weight

    Time frame: Baseline, Week 24

  4. Change from Baseline in Waist Circumference

    Time frame: Baseline, Week 24

  5. Change from Baseline in BMI

    Time frame: Baseline, Week 24

  6. Change from Baseline in HbA1c

    Time frame: Baseline, Week 24

  7. Change from Baseline in fasting plasma glucose

    Time frame: Baseline, Week 24

  8. Change from Baseline in systolic blood pressure

    Time frame: Baseline, Week 24

  9. Change from Baseline in diastolic blood pressure

    Time frame: Baseline, Week 24

  10. Change from Baseline in total cholesterol

    Time frame: Baseline, Week 24

  11. Change from Baseline in low-density lipoprotein cholesterol

    Time frame: Baseline, Week 24

  12. Change from Baseline in high-density lipoprotein cholesterol

    Time frame: Baseline, Week 24

  13. Change from Baseline in triglyceride

    Time frame: Baseline, Week 24

  14. Change from Baseline in serum uric acid

    Time frame: Baseline, Week 12, Week 24

  15. Change from Baseline in IWQoL-Lite-CT questionnaire scores

    Time frame: Baseline, Week 24

07

Study locations

1 site
  • Peking University people's hospital
    Beijing, Beijing Municipality 100044, China
08

References and documents

Publications

  • Ji L, Jiang H, Cheng Z, Li X, Pang S, Zhang Y, Qiu W, Ma Q, Liu Z, Wang Y, Deng H, Du H, Han-Zhang H, Qian L. Mazdutide 9 mg in Chinese adults with a body mass index >/=30 kg/m2 but without diabetes: A phase 2 randomized controlled trial. Med. 2026 May 8;7(5):101063. doi: 10.1016/j.medj.2026.101063. Epub 2026 Mar 23. PubMed 41875890 ↗
  • Ji L, Jiang H, Cheng Z, Qiu W, Liao L, Zhang Y, Li X, Pang S, Zhang L, Chen L, Yang T, Li Y, Qu S, Wen J, Gu J, Deng H, Wang Y, Li L, Han-Zhang H, Ma Q, Qian L. A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity. Nat Commun. 2023 Dec 14;14(1):8289. doi: 10.1038/s41467-023-44067-4. PubMed 38092790 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2021 to primary completion in Mar 2023, 21 months.

Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's 21 months is above that.

Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
May 25, 2021
First posted
May 27, 2021
StartActual
Jun 8, 2021
Primary completionActual
Mar 29, 2023
CompletionActual
Dec 6, 2023
Last update
Nov 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04904913
Responsible party
Sponsor
First posted
May 27, 2021
Start date
Jun 8, 2021
Primary completion
Mar 29, 2023
Completion
Dec 6, 2023
Last update
Nov 17, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mazdutide

Start the discussion